Physician profile
Mark K Lencke
NPI 1720099005
$13,179.05
in general payments reported to CMS, 2019-2025
68 companies · $2,118 in 2025
The $2,118 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,310 · 2020: $747 · 2021: $508 · 2022: $2,369 · 2023: $1,931 · 2024: $2,196 · 2025: $2,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,245.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,289.32 | 2021-2025 | |
| Octapharma USA, INC. | $839.41 | 2022-2024 | Panzyga |
| Teva Pharmaceuticals USA, INC. | $786.30 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Ucb, INC. | $671.90 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Novartis Pharmaceuticals Corporation | $662.97 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $617.24 | 2019-2025 | Nuplazid |
| Neurocrine Biosciences, INC. | $568.96 | 2019-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $537.57 | 2019-2025 | Mavenclad, Mavenclad |
| Eisai INC. | $430.93 | 2019-2025 | |
| Lundbeck LLC | $411.33 | 2019-2025 | Vyepti, Rexulti |
| Alexion Pharmaceuticals, INC. | $400.60 | 2019-2025 | Ultomiris, Soliris |
| Argenx US, INC. | $360.71 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Genentech USA, INC. | $346.72 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Genzyme Corporation | $342.04 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $339.92 | 2019-2021 |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Lencke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.